@article {Schneider2020.11.24.20238212, author = {Benjamin K Schneider and Sebastien Benzekry and Jonathan P Mochel}, title = {Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer}, elocation-id = {2020.11.24.20238212}, year = {2021}, doi = {10.1101/2020.11.24.20238212}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to therapy. 57\% patients are diagnosed in late-stage disease due to the tendency of early-stage NSCLC to be asymptomatic. For patients first diagnosed with metastatic disease the 5-year survival rate is approximately 5\%. To help accelerate the development of novel therapeutics and computer-based tools for optimizing individual therapy, we have collated data from 11 different clinical trials in NSCLC and developed a semi-mechanistic, clinical model of NSCLC growth and pharmacodynamics relative to the various therapeutics represented in the study. In this study, we have produced extremely precise estimates of clinical parameters fundamental to cancer modeling such as the rate of acquired resistance to various pharmaceuticals, the relationship between drug concentration and rate of cancer cell death, as well as the fine temporal dynamics of anti-VEGF therapy. In the simulation sets documented in this study, we have used the model to make meaningful descriptions of efficacy gain in making bevacizumab-antiproliferative combination therapy sequential, over a series of days, rather than concurrent.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors of this manuscript did not receive payment or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As the data is collated from several previous clinical trials in NSCLC, it was unnecessary to seek IRB/oversight body approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this manuscript are only available by direct request to the data administrators via Vivli.com.afolateThe antifolate action of a cytotoxic drug i.e. pemetrexedapoApomab aka DAB4, its chimeric derivative chDAB4, or PRO95780aucThe area under the curve of drug concentration over time, usually interpreted as a measure of exposurebevBevacizumabcarCarboplatinccConcentration, usually concentration as a function of timecisCisplatindocDocetaxeldr5The mechanism of action of Apomab, a monoclonal antibody against death receptor 5effEffectegfrThe egfr-based (endothelial growth factor receptor) mechanism of erlotiniberlErlotinibgemGemcitabinekkRate of passage between compartmentsmicrotThe microtubule-inhibition mechanisms of paclitaxel and docetaxelnSum of primary all tumor volumes i.e. v + vi+ z1+ z2+ z3dnasubThe mechanism of action of gemcitabine whereby it masquerades as a functional nucleoside only to cause masked chain termination when incorporated into DNApacPaclitaxelpemPemetrexedplatThe class of cytotoxics whose mechanism involves platinum i.e. cisplatin, carboplatin, etc.Qα, QρThe effects whereby certain drugs limit the rate of growth of the tumor e.g. cell cycle arrest, nutrient supply disruption, etc.QγThe effect whereby certain drugs kill tumor cells directlytTime in daysvPrimary tumor volume in cm3viVolume of tumor cells which are injured by vegf and microt drugsvegfThe anti-vegf (vascular endothelial growth factor) mechanism of bevacizumabz1{\textendash}3Irreversible cell death compartmentswdA scaling factor between drug concentration and cytotoxic effectλdScaling factor between drug exposure and resistance}, URL = {https://www.medrxiv.org/content/early/2021/05/21/2020.11.24.20238212}, eprint = {https://www.medrxiv.org/content/early/2021/05/21/2020.11.24.20238212.full.pdf}, journal = {medRxiv} }